+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Budesonide Inhaler Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
Budesonide Inhaler Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
Sale

Budesonide Inhaler Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030

  • PDF Icon

    Report

  • 199 Pages
  • May 2025
  • Region: Global, United States
  • 360iResearch™
  • ID: 6011478
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Budesonide Inhaler Market grew from USD 290.37 million in 2024 to USD 317.06 million in 2025. It is expected to continue growing at a CAGR of 9.11%, reaching USD 490.16 million by 2030.

The budesonide inhaler has emerged as a cornerstone therapy in the management of respiratory disorders, particularly asthma and chronic obstructive pulmonary disease. As an inhaled corticosteroid, it offers potent anti-inflammatory effects while minimizing systemic exposure. This executive summary distills the most critical developments, trends, and strategic insights shaping this market. It begins by contextualizing the product’s clinical significance and commercial trajectory, then explores seismic shifts in regulatory frameworks, patient behavior, and technological innovation. From the ripple effects of new U.S. tariffs to nuanced segmentation by device, patient demographics, application, distribution channel, end-user setting, and packaging format, each section offers a focused lens on competitive dynamics. By spotlighting key regional patterns across the Americas, Europe, Middle East & Africa, and Asia-Pacific, and profiling leading companies, this summary equips executives, investors, and clinicians with an actionable roadmap. Throughout, the narrative balances depth with clarity, ensuring that decision-makers can swiftly translate insights into impactful strategies. As we transition through each chapter, anticipate a seamless fusion of data-driven analysis and forward-looking perspectives designed to accelerate growth and optimize patient outcomes.

Transformative Shifts Reshaping the Budesonide Inhaler Ecosystem

Prescription and delivery of inhaled therapies have undergone a remarkable metamorphosis in recent years. Patient expectations have shifted from one-size-fits-all inhalers toward personalized, technology-enabled devices that adapt dosing patterns and track adherence in real time. Simultaneously, digital health platforms now integrate seamlessly with inhaler hardware, delivering remote monitoring and predictive analytics that pre-empt exacerbations and reduce hospital readmissions.

On the regulatory front, expedited review pathways and decentralization of clinical trials have accelerated time to market for novel formulations. Telemedicine has expanded access, enabling clinicians to fine-tune treatment regimens without in-person visits. Meanwhile, payers increasingly reward value-based outcomes, pressuring manufacturers to demonstrate real-world effectiveness beyond traditional endpoints.

Innovation in device design-ranging from soft mist inhalers for enhanced lung deposition to breath-actuated metered-dose inhalers that minimize coordination errors-has redefined patient convenience. Supply chains are also evolving: strategic partnerships with contract manufacturers and local API suppliers mitigate geopolitical risks and tariff pressures. Taken together, these transformative shifts are converging to create a more patient-centric, data-driven, and resilient budesonide inhaler ecosystem.

Cumulative Impact of 2025 U.S. Tariffs on Budesonide Inhalers

In 2025, the United States instituted a series of tariffs targeting imported pharmaceutical excipients, active pharmaceutical ingredients, and delivery devices. Budesonide inhalers, which rely on specialized propellants, inhaler mechanisms, and high-quality APIs, have felt the cumulative impact through higher input costs. Manufacturers have responded by negotiating volume discounts with domestic contract development and manufacturing organizations and by relocating certain assembly operations to U.S. facilities.

These measures have catalyzed a shift toward regional supply hubs, reducing lead times by as much as 20% while containing logistics expenses. Nevertheless, end-users-hospitals, pharmacies, and patients-face pressure from incremental price increases. Payers are scrutinizing formulary placement and tightening reimbursement criteria, spurring manufacturers to emphasize pharmacoeconomic data that highlights reduced exacerbations and long-term cost savings.

On the procurement side, strategic sourcing has become more sophisticated. Expanded vendor qualification processes now include tariff-exposure risk assessments and dual-sourcing strategies. By diversifying raw-material origins and leveraging bonded warehouses, industry leaders are cushioning profit margins against future trade disputes. While initial adjustments required capital reinvestment, the operational resilience achieved promises sustained stability and competitive advantage.

Key Segmentation Insights for Budesonide Inhaler Market Dynamics

A granular look at segmentation reveals the multifaceted dynamics driving this market. Based on device type, the landscape divides into inhalers and nebulizers. Within inhalers, dry powder inhalers, metered-dose inhalers, and soft mist inhalers each compete for adoption. Dry powder formats further differentiate into multi-unit dose inhalers, Podhaler technology, and single-unit dose inhalers, while metered-dose variants include both breath-actuated and pressurized systems. Nebulizer adoption spans portable and tabletop models, reflecting patient mobility needs and healthcare setting constraints.

Patient age segments influence both product design and marketing. The adult cohort comprises middle-aged and young adults, who prioritize device ease of use and digital integration. Geriatric patients split into early and late stages, with late geriatric individuals-especially the frail elderly-requiring devices that minimize manual dexterity demands. Pediatric patients, from infants to toddlers and school-age children, benefit from mask-compatible nebulizers and child-friendly inhaler interfaces.

Therapeutic application further refines demand. Asthma encompasses mild intermittent through severe persistent forms, including refractory asthma subtypes. Chronic obstructive pulmonary disease segments into chronic bronchitis and emphysema, each with distinct dosing regimens and adherence challenges. Nasal polyps represent a smaller yet high-value niche, given the corticosteroid’s efficacy in reducing polyp size and recurrence.

Distribution channels center on prescription-based inhalers, with hospital, online, and retail pharmacies vying for market share. End-user settings range from ambulatory care centers to homecare environments and hospitals and clinics, each demanding tailored packaging and patient education. Finally, product format preferences split between multi-dose packs-refillable or non-refillable-and single-dose formats, driving portfolio strategies to align with both cost-efficiency and adherence goals.

Key Regional Insights Driving Global Budesonide Inhaler Trends

Regional dynamics are shaping growth trajectories and investment priorities. In the Americas, robust reimbursement frameworks and widespread insurance coverage underpin high adoption rates of advanced delivery systems, spurring manufacturers to innovate within the premium segment. Meanwhile, Latin American markets are experiencing incremental growth as generic competition drives affordability and local partnerships expand distribution.

Across Europe, Middle East & Africa, regulatory harmonization under initiatives like the European Medicines Agency’s central approval system accelerates product launches, yet fragmented reimbursement landscapes require nuanced payer engagement. In the Middle East, government subsidies support access, while African markets emphasize affordability and cold-chain logistics solutions.

In Asia-Pacific, rapid urbanization and rising respiratory disease prevalence generate strong demand. Markets such as China, India, and Southeast Asia demonstrate growing interest in digital adherence tools and portable nebulizers. Local manufacturing incentives and public-private collaborations are easing access barriers, and regional hubs are scaling production capacity to serve both domestic and export markets.

Key Company Strategies Shaping the Budesonide Inhaler Arena

Competition is intensifying as established pharmaceutical powerhouses and nimble specialists vie for leadership. Abbott Laboratories leverages its respiratory portfolio breadth to cross-sell inhaled therapies, while AstraZeneca PLC continues to invest in next-generation device platforms. Chiesi Farmaceutici S.p.A. differentiates through specialty inhalers designed for complex chronic obstructive pulmonary disease cases, and Cipla Limited emphasizes cost-effective generics and patient affordability in emerging economies.

Cosmo Pharmaceuticals N.V. and Lunan Pharmaceutical Group pursue strategic licensing deals to expand their inhalation technology suites, whereas Lupin Limited and Manus Aktteva Biopharma LLP focus on high-purity budesonide APIs with enhanced formulation stability. Novartis International AG integrates digital adherence trackers into its devices, and Orion Corporation partners with technology startups to pilot AI-driven dosing recommendations.

Pfizer Inc. and Takeda Pharmaceutical Company Limited are strengthening their supply chains through vertical integration, and Synmosa Biopharma Corporation explores novel propellant alternatives to meet environmental regulations. Viatris Inc. consolidates global manufacturing assets to optimize production costs and ensure consistent product availability.

Actionable Recommendations for Industry Leaders

To stay ahead in this evolving market, industry leaders should prioritize the following actions:
  1. Integrate digital adherence platforms directly into inhaler ecosystems, capturing real-world usage data to support outcomes-based contracting and strengthen payer relationships.
  2. Diversify supply chains by establishing regional manufacturing hubs and dual-sourcing critical components, insulating operations from tariff fluctuations and geopolitical disruptions.
  3. Develop modular device architectures that enable rapid customization for different age groups, therapeutic applications, and regional regulatory requirements, accelerating time to market.
  4. Forge strategic alliances with patient advocacy groups and clinical research networks to co-create educational initiatives, enhancing disease awareness and improving long-term adherence metrics.
  5. Invest in environmentally sustainable propellants and packaging solutions to align with global regulatory mandates and meet growing consumer demand for eco-responsible products.
By executing these recommendations, companies can balance cost containment with differentiation, driving both commercial success and patient benefit.

Conclusion and Strategic Takeaways

The budesonide inhaler market stands at the intersection of clinical innovation, regulatory evolution, and shifting patient expectations. Manufacturers that harness digital health, diversify supply chains, and tailor products to finely segmented patient cohorts will unlock competitive moats. Regional nuances-from reimbursement schemes in the Americas to emerging partnerships in Asia-Pacific-underscore the importance of adaptive strategies. Moreover, strategic collaboration across the value chain, from API suppliers to patient communities, will reinforce resilience against external shocks like tariff adjustments.

Looking ahead, the convergence of personalized medicine and environmental stewardship will define the next chapter. Leaders who embed data-driven decision making, sustainability, and patient engagement at the core of their operations will not only capture market share but also elevate standards of care for millions living with respiratory diseases.

Market Segmentation & Coverage

This research report categorizes the Budesonide Inhaler Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Inhalers
    • Dry Powder Inhalers
      • Multi-Unit Dose Inhalers
      • Podhaler Technology
      • Single-Unit Dose Inhalers
    • Metered-Dose Inhalers
      • Breath-Actuated Inhalers
      • Pressurized Inhalers
    • Soft Mist Inhalers
  • Nebulizers
    • Portable Nebulizers
    • Tabletop Nebulizers
  • Adult
    • Middle-Aged Adults
    • Young Adults
  • Geriatric
    • Early Geriatric
    • Late Geriatric
      • Frail Elderly
  • Pediatric
    • Infants
    • School-Age Children
    • Toddlers
  • Asthma
    • Mild Intermittent Asthma
    • Mild Persistent Asthma
    • Moderate Persistent Asthma
    • Severe Persistent Asthma
      • Refractory Asthma
  • Chronic Obstructive Pulmonary Disease (COPD)
    • Chronic Bronchitis
    • Emphysema
  • Nasal Polyps
  • Prescription Based Inhalers
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
  • Ambulatory Care Centers
  • Homecare Settings
  • Hospitals And Clinics
  • Multi-Dose Packs
    • Non-Refillable Packs
    • Refillable Packs
  • Single-Dose Packs

This research report categorizes the Budesonide Inhaler Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Budesonide Inhaler Market to delves into recent significant developments and analyze trends in each of the following companies:

  • Abbott Laboratories
  • AstraZeneca PLC
  • Chiesi Farmaceutici S.p.A.
  • Cipla Limited
  • Cosmo Pharmaceuticals N.V.
  • Lunan Pharmaceutical Group
  • Lupin Limited
  • Manus Aktteva Biopharma LLP
  • Novartis International AG
  • Orion Corporation
  • Pfizer Inc.
  • Synmosa Biopharma Corporation
  • Takeda Pharmaceutical Company Limited
  • Viatris Inc.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Budesonide Inhaler Market, by Device Type
8.1. Introduction
8.2. Inhalers
8.2.1. Dry Powder Inhalers
8.2.1.1. Multi-Unit Dose Inhalers
8.2.1.2. Podhaler Technology
8.2.1.3. Single-Unit Dose Inhalers
8.2.2. Metered-Dose Inhalers
8.2.2.1. Breath-Actuated Inhalers
8.2.2.2. Pressurized Inhalers
8.2.3. Soft Mist Inhalers
8.3. Nebulizers
8.3.1. Portable Nebulizers
8.3.2. Tabletop Nebulizers
9. Budesonide Inhaler Market, by Patient Age
9.1. Introduction
9.2. Adult
9.2.1. Middle-Aged Adults
9.2.2. Young Adults
9.3. Geriatric
9.3.1. Early Geriatric
9.3.2. Late Geriatric
9.3.2.1. Frail Elderly
9.4. Pediatric
9.4.1. Infants
9.4.2. School-Age Children
9.4.3. Toddlers
10. Budesonide Inhaler Market, by Application
10.1. Introduction
10.2. Asthma
10.2.1. Mild Intermittent Asthma
10.2.2. Mild Persistent Asthma
10.2.3. Moderate Persistent Asthma
10.2.4. Severe Persistent Asthma
10.2.4.1. Refractory Asthma
10.3. Chronic Obstructive Pulmonary Disease (COPD)
10.3.1. Chronic Bronchitis
10.3.2. Emphysema
10.4. Nasal Polyps
11. Budesonide Inhaler Market, by Mode Of Distribution
11.1. Introduction
11.2. Prescription Based Inhalers
11.2.1. Hospital Pharmacies
11.2.2. Online Pharmacies
11.2.3. Retail Pharmacies
12. Budesonide Inhaler Market, by End-User
12.1. Introduction
12.2. Ambulatory Care Centers
12.3. Homecare Settings
12.4. Hospitals And Clinics
13. Budesonide Inhaler Market, by Product Format
13.1. Introduction
13.2. Multi-Dose Packs
13.2.1. Non-Refillable Packs
13.2.2. Refillable Packs
13.3. Single-Dose Packs
14. Americas Budesonide Inhaler Market
14.1. Introduction
14.2. Argentina
14.3. Brazil
14.4. Canada
14.5. Mexico
14.6. United States
15. Asia-Pacific Budesonide Inhaler Market
15.1. Introduction
15.2. Australia
15.3. China
15.4. India
15.5. Indonesia
15.6. Japan
15.7. Malaysia
15.8. Philippines
15.9. Singapore
15.10. South Korea
15.11. Taiwan
15.12. Thailand
15.13. Vietnam
16. Europe, Middle East & Africa Budesonide Inhaler Market
16.1. Introduction
16.2. Denmark
16.3. Egypt
16.4. Finland
16.5. France
16.6. Germany
16.7. Israel
16.8. Italy
16.9. Netherlands
16.10. Nigeria
16.11. Norway
16.12. Poland
16.13. Qatar
16.14. Russia
16.15. Saudi Arabia
16.16. South Africa
16.17. Spain
16.18. Sweden
16.19. Switzerland
16.20. Turkey
16.21. United Arab Emirates
16.22. United Kingdom
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Abbott Laboratories
17.3.2. AstraZeneca PLC
17.3.3. Chiesi Farmaceutici S.p.A.
17.3.4. Cipla Limited
17.3.5. Cosmo Pharmaceuticals N.V.
17.3.6. Lunan Pharmaceutical Group
17.3.7. Lupin Limited
17.3.8. Manus Aktteva Biopharma LLP
17.3.9. Novartis International AG
17.3.10. Orion Corporation
17.3.11. Pfizer Inc.
17.3.12. Synmosa Biopharma Corporation
17.3.13. Takeda Pharmaceutical Company Limited
17.3.14. Viatris Inc.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. BUDESONIDE INHALER MARKET MULTI-CURRENCY
FIGURE 2. BUDESONIDE INHALER MARKET MULTI-LANGUAGE
FIGURE 3. BUDESONIDE INHALER MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL BUDESONIDE INHALER MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL BUDESONIDE INHALER MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BUDESONIDE INHALER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BUDESONIDE INHALER MARKET SIZE, BY DEVICE TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL BUDESONIDE INHALER MARKET SIZE, BY DEVICE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BUDESONIDE INHALER MARKET SIZE, BY PATIENT AGE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL BUDESONIDE INHALER MARKET SIZE, BY PATIENT AGE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BUDESONIDE INHALER MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL BUDESONIDE INHALER MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL BUDESONIDE INHALER MARKET SIZE, BY MODE OF DISTRIBUTION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL BUDESONIDE INHALER MARKET SIZE, BY MODE OF DISTRIBUTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL BUDESONIDE INHALER MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL BUDESONIDE INHALER MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL BUDESONIDE INHALER MARKET SIZE, BY PRODUCT FORMAT, 2024 VS 2030 (%)
FIGURE 18. GLOBAL BUDESONIDE INHALER MARKET SIZE, BY PRODUCT FORMAT, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS BUDESONIDE INHALER MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS BUDESONIDE INHALER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES BUDESONIDE INHALER MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES BUDESONIDE INHALER MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC BUDESONIDE INHALER MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC BUDESONIDE INHALER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. EUROPE, MIDDLE EAST & AFRICA BUDESONIDE INHALER MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. EUROPE, MIDDLE EAST & AFRICA BUDESONIDE INHALER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. BUDESONIDE INHALER MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. BUDESONIDE INHALER MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. BUDESONIDE INHALER MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BUDESONIDE INHALER MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BUDESONIDE INHALER MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BUDESONIDE INHALER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL BUDESONIDE INHALER MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL BUDESONIDE INHALER MARKET SIZE, BY INHALERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BUDESONIDE INHALER MARKET SIZE, BY DRY POWDER INHALERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BUDESONIDE INHALER MARKET SIZE, BY MULTI-UNIT DOSE INHALERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BUDESONIDE INHALER MARKET SIZE, BY PODHALER TECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BUDESONIDE INHALER MARKET SIZE, BY SINGLE-UNIT DOSE INHALERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BUDESONIDE INHALER MARKET SIZE, BY DRY POWDER INHALERS, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BUDESONIDE INHALER MARKET SIZE, BY METERED-DOSE INHALERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BUDESONIDE INHALER MARKET SIZE, BY BREATH-ACTUATED INHALERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BUDESONIDE INHALER MARKET SIZE, BY PRESSURIZED INHALERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BUDESONIDE INHALER MARKET SIZE, BY METERED-DOSE INHALERS, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BUDESONIDE INHALER MARKET SIZE, BY SOFT MIST INHALERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BUDESONIDE INHALER MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BUDESONIDE INHALER MARKET SIZE, BY NEBULIZERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BUDESONIDE INHALER MARKET SIZE, BY PORTABLE NEBULIZERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BUDESONIDE INHALER MARKET SIZE, BY TABLETOP NEBULIZERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BUDESONIDE INHALER MARKET SIZE, BY NEBULIZERS, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BUDESONIDE INHALER MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BUDESONIDE INHALER MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BUDESONIDE INHALER MARKET SIZE, BY MIDDLE-AGED ADULTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BUDESONIDE INHALER MARKET SIZE, BY YOUNG ADULTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BUDESONIDE INHALER MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BUDESONIDE INHALER MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL BUDESONIDE INHALER MARKET SIZE, BY EARLY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL BUDESONIDE INHALER MARKET SIZE, BY LATE GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL BUDESONIDE INHALER MARKET SIZE, BY FRAIL ELDERLY, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL BUDESONIDE INHALER MARKET SIZE, BY LATE GERIATRIC, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL BUDESONIDE INHALER MARKET SIZE, BY GERIATRIC, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL BUDESONIDE INHALER MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL BUDESONIDE INHALER MARKET SIZE, BY INFANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL BUDESONIDE INHALER MARKET SIZE, BY SCHOOL-AGE CHILDREN, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL BUDESONIDE INHALER MARKET SIZE, BY TODDLERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL BUDESONIDE INHALER MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL BUDESONIDE INHALER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL BUDESONIDE INHALER MARKET SIZE, BY ASTHMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL BUDESONIDE INHALER MARKET SIZE, BY MILD INTERMITTENT ASTHMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL BUDESONIDE INHALER MARKET SIZE, BY MILD PERSISTENT ASTHMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL BUDESONIDE INHALER MARKET SIZE, BY MODERATE PERSISTENT ASTHMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL BUDESONIDE INHALER MARKET SIZE, BY SEVERE PERSISTENT ASTHMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL BUDESONIDE INHALER MARKET SIZE, BY REFRACTORY ASTHMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL BUDESONIDE INHALER MARKET SIZE, BY SEVERE PERSISTENT ASTHMA, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL BUDESONIDE INHALER MARKET SIZE, BY ASTHMA, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL BUDESONIDE INHALER MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL BUDESONIDE INHALER MARKET SIZE, BY CHRONIC BRONCHITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL BUDESONIDE INHALER MARKET SIZE, BY EMPHYSEMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL BUDESONIDE INHALER MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
TABLE 52. GLOBAL BUDESONIDE INHALER MARKET SIZE, BY NASAL POLYPS, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL BUDESONIDE INHALER MARKET SIZE, BY MODE OF DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL BUDESONIDE INHALER MARKET SIZE, BY PRESCRIPTION BASED INHALERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL BUDESONIDE INHALER MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL BUDESONIDE INHALER MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL BUDESONIDE INHALER MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL BUDESONIDE INHALER MARKET SIZE, BY PRESCRIPTION BASED INHALERS, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL BUDESONIDE INHALER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL BUDESONIDE INHALER MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL BUDESONIDE INHALER MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL BUDESONIDE INHALER MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL BUDESONIDE INHALER MARKET SIZE, BY PRODUCT FORMAT, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL BUDESONIDE INHALER MARKET SIZE, BY MULTI-DOSE PACKS, BY REGION, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL BUDESONIDE INHALER MARKET SIZE, BY NON-REFILLABLE PACKS, BY REGION, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL BUDESONIDE INHALER MARKET SIZE, BY REFILLABLE PACKS, BY REGION, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL BUDESONIDE INHALER MARKET SIZE, BY MULTI-DOSE PACKS, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL BUDESONIDE INHALER MARKET SIZE, BY SINGLE-DOSE PACKS, BY REGION, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS BUDESONIDE INHALER MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS BUDESONIDE INHALER MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS BUDESONIDE INHALER MARKET SIZE, BY DRY POWDER INHALERS, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS BUDESONIDE INHALER MARKET SIZE, BY METERED-DOSE INHALERS, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS BUDESONIDE INHALER MARKET SIZE, BY NEBULIZERS, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS BUDESONIDE INHALER MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS BUDESONIDE INHALER MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS BUDESONIDE INHALER MARKET SIZE, BY GERIATRIC, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS BUDESONIDE INHALER MARKET SIZE, BY LATE GERIATRIC, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS BUDESONIDE INHALER MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS BUDESONIDE INHALER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 80. AMERICAS BUDESONIDE INHALER MARKET SIZE, BY ASTHMA, 2018-2030 (USD MILLION)
TABLE 81. AMERICAS BUDESONIDE INHALER MARKET SIZE, BY SEVERE PERSISTENT ASTHMA, 2018-2030 (USD MILLION)
TABLE 82. AMERICAS BUDESONIDE INHALER MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
TABLE 83. AMERICAS BUDESONIDE INHALER MARKET SIZE, BY MODE OF DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 84. AMERICAS BUDESONIDE INHALER MARKET SIZE, BY PRESCRIPTION BASED INHALERS, 2018-2030 (USD MILLION)
TABLE 85. AMERICAS BUDESONIDE INHALER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 86. AMERICAS BUDESONIDE INHALER MARKET SIZE, BY PRODUCT FORMAT, 2018-2030 (USD MILLION)
TABLE 87. AMERICAS BUDESONIDE INHALER MARKET SIZE, BY MULTI-DOSE PACKS, 2018-2030 (USD MILLION)
TABLE 88. AMERICAS BUDESONIDE INHALER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 89. ARGENTINA BUDESONIDE INHALER MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 90. ARGENTINA BUDESONIDE INHALER MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
TABLE 91. ARGENTINA BUDESONIDE INHALER MARKET SIZE, BY DRY POWDER INHALERS, 2018-2030 (USD MILLION)
TABLE 92. ARGENTINA BUDESONIDE INHALER MARKET SIZE, BY METERED-DOSE INHALERS, 2018-2030 (USD MILLION)
TABLE 93. ARGENTINA BUDESONIDE INHALER MARKET SIZE, BY NEBULIZERS, 2018-2030 (USD MILLION)
TABLE 94. ARGENTINA BUDESONIDE INHALER MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 95. ARGENTINA BUDESONIDE INHALER MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 96. ARGENTINA BUDESONIDE INHALER MARKET SIZE, BY GERIATRIC, 2018-2030 (USD MILLION)
TABLE 97. ARGENTINA BUDESONIDE INHALER MARKET SIZE, BY LATE GERIATRIC, 2018-2030 (USD MILLION)
TABLE 98. ARGENTINA BUDESONIDE INHALER MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 99. ARGENTINA BUDESONIDE INHALER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 100. ARGENTINA BUDESONIDE INHALER MARKET SIZE, BY ASTHMA, 2018-2030 (USD MILLION)
TABLE 101. ARGENTINA BUDESONIDE INHALER MARKET SIZE, BY SEVERE PERSISTENT ASTHMA, 2018-2030 (USD MILLION)
TABLE 102. ARGENTINA BUDESONIDE INHALER MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
TABLE 103. ARGENTINA BUDESONIDE INHALER MARKET SIZE, BY MODE OF DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 104. ARGENTINA BUDESONIDE INHALER MARKET SIZE, BY PRESCRIPTION BASED INHALERS, 2018-2030 (USD MILLION)
TABLE 105. ARGENTINA BUDESONIDE INHALER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 106. ARGENTINA BUDESONIDE INHALER MARKET SIZE, BY PRODUCT FORMAT, 2018-2030 (USD MILLION)
TABLE 107. ARGENTINA BUDESONIDE INHALER MARKET SIZE, BY MULTI-DOSE PACKS, 2018-2030 (USD MILLION)
TABLE 108. BRAZIL BUDESONIDE INHALER MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 109. BRAZIL BUDESONIDE INHALER MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
TABLE 110. BRAZIL BUDESONIDE INHALER MARKET SIZE, BY DRY POWDER INHALERS, 2018-2030 (USD MILLION)
TABLE 111. BRAZIL BUDESONIDE INHALER MARKET SIZE, BY METERED-DOSE INHALERS, 2018-2030 (USD MILLION)
TABLE 112. BRAZIL BUDESONIDE INHALER MARKET SIZE, BY NEBULIZERS, 2018-2030 (USD MILLION)
TABLE 113. BRAZIL BUDESONIDE INHALER MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 114. BRAZIL BUDESONIDE INHALER MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 115. BRAZIL BUDESONIDE INHALER MARKET SIZE, BY GERIATRIC, 2018-2030 (USD MILLION)
TABLE 116. BRAZIL BUDESONIDE INHALER MARKET SIZE, BY LATE GERIATRIC, 2018-2030 (USD MILLION)
TABLE 117. BRAZIL BUDESONIDE INHALER MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 118. BRAZIL BUDESONIDE INHALER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 119. BRAZIL BUDESONIDE INHALER MARKET SIZE, BY ASTHMA, 2018-2030 (USD MILLION)
TABLE 120. BRAZIL BUDESONIDE INHALER MARKET SIZE, BY SEVERE PERSISTENT ASTHMA, 2018-2030 (USD MILLION)
TABLE 121. BRAZIL BUDESONIDE INHALER MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
TABLE 122. BRAZIL BUDESONIDE INHALER MARKET SIZE, BY MODE OF DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 123. BRAZIL BUDESONIDE INHALER MARKET SIZE, BY PRESCRIPTION BASED INHALERS, 2018-2030 (USD MILLION)
TABLE 124. BRAZIL BUDESONIDE INHALER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 125. BRAZIL BUDESONIDE INHALER MARKET SIZE, BY PRODUCT FORMAT, 2018-2030 (USD MILLION)
TABLE 126. BRAZIL BUDESONIDE INHALER MARKET SIZE, BY MULTI-DOSE PACKS, 2018-2030 (USD MILLION)
TABLE 127. CANADA BUDESONIDE INHALER MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 128. CANADA BUDESONIDE INHALER MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
TABLE 129. CANADA BUDESONIDE INHALER MARKET SIZE, BY DRY POWDER INHALERS, 2018-2030 (USD MILLION)
TABLE 130. CANADA BUDESONIDE INHALER MARKET SIZE, BY METERED-DOSE INHALERS, 2018-2030 (USD MILLION)
TABLE 131. CANADA BUDESONIDE INHALER MARKET SIZE, BY NEBULIZERS, 2018-2030 (USD MILLION)
TABLE 132. CANADA BUDESONIDE INHALER MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 133. CANADA BUDESONIDE INHALER MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 134. CANADA BUDESONIDE INHALER MARKET SIZE, BY GERIATRIC, 2018-2030 (USD MILLION)
TABLE 135. CANADA BUDESONIDE INHALER MARKET SIZE, BY LATE GERIATRIC, 2018-2030 (USD MILLION)
TABLE 136. CANADA BUDESONIDE INHALER MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 137. CANADA BUDESONIDE INHALER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 138. CANADA BUDESONIDE INHALER MARKET SIZE, BY ASTHMA, 2018-2030 (USD MILLION)
TABLE 139. CANADA BUDESONIDE INHALER MARKET SIZE, BY SEVERE PERSISTENT ASTHMA, 2018-2030 (USD MILLION)
TABLE 140. CANADA BUDESONIDE INHALER MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
TABLE 141. CANADA BUDESONIDE INHALER MARKET SIZE, BY MODE OF DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 142. CANADA BUDESONIDE INHALER MARKET SIZE, BY PRESCRIPTION BASED INHALERS, 2018-2030 (USD MILLION)
TABLE 143. CANADA BUDESONIDE INHALER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 144. CANADA BUDESONIDE INHALER MARKET SIZE, BY PRODUCT FORMAT, 2018-2030 (USD MILLION)
TABLE 145. CANADA BUDESONIDE INHALER MARKET SIZE, BY MULTI-DOSE PACKS, 2018-2030 (USD MILLION)
TABLE 146. MEXICO BUDESONIDE INHALER MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 147. MEXICO BUDESONIDE INHALER MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
TABLE 148. MEXICO BUDESONIDE INHALER MARKET SIZE, BY DRY POWDER INHALERS, 2018-2030 (USD MILLION)
TABLE 149. MEXICO BUDESONIDE INHALER MARKET SIZE, BY METERED-DOSE INHALERS, 2018-2030 (USD MILLION)
TABLE 150. MEXICO BUDESONIDE INHALER MARKET SIZE, BY NEBULIZERS, 2018-2030 (USD MILLION)
TABLE 151. MEXICO BUDESONIDE INHALER MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 152. MEXICO BUDESONIDE INHALER MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 153. MEXICO BUDESONIDE INHALER MARKET SIZE, BY GERIATRIC, 2018-2030 (USD MILLION)
TABLE 154. MEXICO BUDESONIDE INHALER MARKET SIZE, BY LATE GERIATRIC, 2018-2030 (USD MILLION)
TABLE 155. MEXICO BUDESONIDE INHALER MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 156. MEXICO BUDESONIDE INHALER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 157. MEXICO BUDESONIDE INHALER MARKET SIZE, BY ASTHMA, 2018-2030 (USD MILLION)
TABLE 158. MEXICO BUDESONIDE INHALER MARKET SIZE, BY SEVERE PERSISTENT ASTHMA, 2018-2030 (USD MILLION)
TABLE 159. MEXICO BUDESONIDE INHALER MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
TABLE 160. MEXICO BUDESONIDE INHALER MARKET SIZE, BY MODE OF DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 161. MEXICO BUDESONIDE INHALER MARKET SIZE, BY PRESCRIPTION BASED INHALERS, 2018-2030 (USD MILLION)
TABLE 162. MEXICO BUDESONIDE INHALER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 163. MEXICO BUDESONIDE INHALER MARKET SIZE, BY PRODUCT FORMAT, 2018-2030 (USD MILLION)
TABLE 164. MEXICO BUDESONIDE INHALER MARKET SIZE, BY MULTI-DOSE PACKS, 2018-2030 (USD MILLION)
TABLE 165. UNITED STATES BUDESONIDE INHALER MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 166. UNITED STATES BUDESONIDE INHALER MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
TABLE 167. UNITED STATES BUDESONIDE INHALER MARKET SIZE, BY DRY POWDER INHALERS, 2018-2030 (USD MILLION)
TABLE 168. UNITED STATES BUDESONIDE INHALER MARKET SIZE, BY METERED-DOSE INHALERS, 2018-2030 (USD MILLION)
TABLE 169. UNITED STATES BUDESONIDE INHALER MARKET SIZE, BY NEBULIZERS, 2018-2030 (USD MILLION)
TABLE 170. UNITED STATES BUDESONIDE INHALER MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 171. UNITED STATES BUDESONIDE INHALER MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 172. UNITED STATES BUDESONIDE INHALER MARKET SIZE, BY GERIATRIC, 2018-2030 (USD MILLION)
TABLE 173. UNITED STATES BUDESONIDE INHALER MARKET SIZE, BY LATE GERIATRIC, 2018-2030 (USD MILLION)
TABLE 174. UNITED STATES BUDESONIDE INHALER MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 175. UNITED STATES BUDESONIDE INHALER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 176. UNITED STATES BUDESONIDE INHALER MARKET SIZE, BY ASTHMA, 2018-2030 (USD MILLION)
TABLE 177. UNITED STATES BUDESONIDE INHALER MARKET SIZE, BY SEVERE PERSISTENT ASTHMA, 2018-2030 (USD MILLION)
TABLE 178. UNITED STATES BUDESONIDE INHALER MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
TABLE 179. UNITED STATES BUDESONIDE INHALER MARKET SIZE, BY MODE OF DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 180. UNITED STATES BUDESONIDE INHALER MARKET SIZE, BY PRESCRIPTION BASED INHALERS, 2018-2030 (USD MILLION)
TABLE 181. UNITED STATES BUDESONIDE INHALER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 182. UNITED STATES BUDESONIDE INHALER MARKET SIZE, BY PRODUCT FORMAT, 2018-2030 (USD MILLION)
TABLE 183. UNITED STATES BUDESONIDE INHALER MARKET SIZE, BY MULTI-DOSE PACKS, 2018-2030 (USD MILLION)
TABLE 184. UNITED STATES BUDESONIDE INHALER MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 185. ASIA-PACIFIC BUDESONIDE INHALER MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 186. ASIA-PACIFIC BUDESONIDE INHALER MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
TABLE 187. ASIA-PACIFIC BUDESONIDE INHALER MARKET SIZE, BY DRY POWDER INHALERS, 2018-2030 (USD MILLION)
TABLE 188. ASIA-PACIFIC BUDESONIDE INHALER MARKET SIZE, BY METERED-DOSE INHALERS, 2018-2030 (USD MILLION)
TABLE 189. ASIA-PACIFIC BUDESONIDE INHALER MARKET SIZE, BY NEBULIZERS, 2018-2030 (USD MILLION)
TABLE 190. ASIA-PACIFIC BUDESONIDE INHALER MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 191. ASIA-PACIFIC BUDESONIDE INHALER MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 192. ASIA-PACIFIC BUDESONIDE INHALER MARKET SIZE, BY GERIATRIC, 2018-2030 (USD MILLION)
TABLE 193. ASIA-PACIFIC BUDESONIDE INHALER MARKET SIZE, BY LATE GERIATRIC, 2018-2030 (USD MILLION)
TABLE 194. ASIA-PACIFIC BUDESONIDE INHALER MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 195. ASIA-PACIFIC BUDESONIDE INHALER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 196. ASIA-PACIFIC BUDESONIDE INHALER MARKET SIZE, BY ASTHMA, 2018-2030 (USD MILLION)
TABLE 197. ASIA-PACIFIC BUDESONIDE INHALER MARKET SIZE, BY SEVERE PERSISTENT ASTHMA, 2018-2030 (USD MILLION)
TABLE 198. ASIA-PACIFIC BUDESONIDE INHALER MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
TABLE 199. ASIA-PACIFIC BUDESONIDE INHALER MARKET SIZE, BY MODE OF DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 200. ASIA-PACIFIC BUDESONIDE INHALER MARKET SIZE, BY PRESCRIPTION BASED INHALERS, 2018-2030 (USD MILLION)
TABLE 201. ASIA-PACIFIC BUDESONIDE INHALER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 202. ASIA-PACIFIC BUDESONIDE INHALER MARKET SIZE, BY PRODUCT FORMAT, 2018-2030 (USD MILLION)
TABLE 203. ASIA-PACIFIC BUDESONIDE INHALER MARKET SIZE, BY MULTI-DOSE PACKS, 2018-2030 (USD MILLION)
TABLE 204. ASIA-PACIFIC BUDESONIDE INHALER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 205. AUSTRALIA BUDESONIDE INHALER MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 206. AUSTRALIA BUDESONIDE INHALER MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
TABLE 207. AUSTRALIA BUDESONIDE INHALER MARKET SIZE, BY DRY POWDER INHALERS, 2018-2030 (USD MILLION)
TABLE 208. AUSTRALIA BUDESONIDE INHALER MARKET SIZE, BY METERED-DOSE INHALERS, 2018-2030 (USD MILLION)
TABLE 209. AUSTRALIA BUDESONIDE INHALER MARKET SIZE, BY NEBULIZERS, 2018-2030 (USD MILLION)
TABLE 210. AUSTRALIA BUDESONIDE INHALER MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 211. AUSTRALIA BUDESONIDE INHALER MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 212. AUSTRALIA BUDESONIDE INHALER MARKET SIZE, BY GERIATRIC, 2018-2030 (USD MILLION)
TABLE 213. AUSTRALIA BUDESONIDE INHALER MARKET SIZE, BY LATE GERIATRIC, 2018-2030 (USD MILLION)
TABLE 214. AUSTRALIA BUDESONIDE INHALER MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 215. AUSTRALIA BUDESONIDE INHALER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 216. AUSTRALIA BUDESONIDE INHALER MARKET SIZE, BY ASTHMA, 2018-2030 (USD MILLION)
TABLE 217. AUSTRALIA BUDESONIDE INHALER MARKET SIZE, BY SEVERE PERSISTENT ASTHMA, 2018-2030 (USD MILLION)
TABLE 218. AUSTRALIA BUDESONIDE INHALER MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
TABLE 219. AUSTRALIA BUDESONIDE INHALER MARKET SIZE, BY MODE OF DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 220. AUSTRALIA BUDESONIDE INHALER MARKET SIZE, BY PRESCRIPTION BASED INHALERS, 2018-2030 (USD MILLION)
TABLE 221. AUSTRALIA BUDESONIDE INHALER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 222. AUSTRALIA BUDESONIDE INHALER MARKET SIZE, BY PRODUCT FORMAT, 2018-2030 (USD MILLION)
TABLE 223. AUSTRALIA BUDESONIDE INHALER MARKET SIZE, BY MULTI-DOSE PACKS, 2018-2030 (USD MILLION)
TABLE 224. CHINA BUDESONIDE INHALER MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 225. CHINA BUDESONIDE INHALER MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
TABLE 226. CHINA BUDESONIDE INHALER MARKET SIZE, BY DRY POWDER INHALERS, 2018-2030 (USD MILLION)
TABLE 227. CHINA BUDESONIDE INHALER MARKET SIZE, BY METERED-DOSE INHALERS, 2018-2030 (USD MILLION)
TABLE 228. CHINA BUDESONIDE INHALER MARKET SIZE, BY NEBULIZERS, 2018-2030 (USD MILLION)
TABLE 229. CHINA BUDESONIDE INHALER MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 230. CHINA BUDESONIDE INHALER MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 231. CHINA BUDESONIDE INHALER MARKET SIZE, BY GERIATRIC, 2018-2030 (USD MILLION)
TABLE 232. CHINA BUDESONIDE INHALER MARKET SIZE, BY LATE GERIATRIC, 2018-2030 (USD MILLION)
TABLE 233. CHINA BUDESONIDE INHALER MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 234. CHINA BUDESONIDE INHALER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 235. CHINA BUDESONIDE INHALER MARKET SIZE, BY ASTHMA, 2018-2030 (USD MILLION)
TABLE 236. CHINA BUDESONIDE INHALER MARKET SIZE, BY SEVERE PERSISTENT ASTHMA, 2018-2030 (USD MILLION)
TABLE 237. CHINA BUDESONIDE INHALER MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
TABLE 238. CHINA BUDESONIDE INHALER MARKET SIZE, BY MODE OF DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 239. CHINA BUDESONIDE INHALER MARKET SIZE, BY PRESCRIPTION BASED INHALERS, 2018-2030 (USD MILLION)
TABLE 240. CHINA BUDESONIDE INHALER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 241. CHINA BUDESONIDE INHALER MARKET SIZE, BY PRODUCT FORMAT, 2018-2030 (USD MILLION)
TABLE 242. CHINA BUDESONIDE INHALER MARKET SIZE, BY MULTI-DOSE PACKS, 2018-2030 (USD MILLION)
TABLE 243. INDIA BUDESONIDE INHALER MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 244. INDIA BUDESONIDE INHALER MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
TABLE 245. INDIA BUDESONIDE INHALER MARKET SIZE, BY DRY POWDER INHALERS, 2018-2030 (USD MILLION)
TABLE 246. INDIA BUDESONIDE INHALER MARKET SIZE, BY METERED-DOSE INHALERS, 2018-2030 (USD MILLION)
TABLE 247. INDIA BUDESONIDE INHALER MARKET SIZE, BY NEBULIZERS, 2018-2030 (USD MILLION)
TABLE 248. INDIA BUDESONIDE INHALER MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 249. INDIA BUDESONIDE INHALER MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 250. INDIA BUDESONIDE INHALER MARKET SIZE, BY GERIATRIC, 2018-2030 (USD MILLION)
TABLE 251. INDIA BUDESONIDE INHALER MARKET SIZE, BY LATE GERIATRIC, 2018-2030 (USD MILLION)
TABLE 252. INDIA BUDESONIDE INHALER MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 253. INDIA BUDESONIDE INHALER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 254. INDIA BUDESONIDE INHALER MARKET SIZE, BY ASTHMA, 2018-2030 (USD MILLION)
TABLE 255. INDIA BUDESONIDE INHALER MARKET SIZE, BY SEVERE PERSISTENT ASTHMA, 2018-2030 (USD MILLION)
TABLE 256. INDIA BUDESONIDE INHALER MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
TABLE 257. INDIA BUDESONIDE INHALER MARKET SIZE, BY MODE OF DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 258. INDIA BUDESONIDE INHALER MARKET SIZE, BY PRESCRIPTION BASED INHALERS, 2018-2030 (USD MILLION)
TABLE 259. INDIA BUDESONIDE INHALER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 260. INDIA BUDESONIDE INHALER MARKET SIZE, BY PRODUCT FORMAT, 2018-2030 (USD MILLION)
TABLE 261. INDIA BUDESONIDE INHALER MARKET SIZE, BY MULTI-DOSE PACKS, 2018-2030 (USD MILLION)
TABLE 262. INDONESIA BUDESONIDE INHALER MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 263. INDONESIA BUDESONIDE INHALER MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
TABLE 264. INDONESIA BUDESONIDE INHALER MARKET SIZE, BY DRY POWDER INHALERS, 2018-2030 (USD MILLION)
TABLE 265. INDONESIA BUDESONIDE INHALER MARKET SIZE, BY METERED-DOSE INHALERS, 2018-2030 (USD MILLION)
TABLE 266. INDONESIA BUDESONIDE INHALER MARKET SIZE, BY NEBULIZERS, 2018-2030 (USD MILLION)
TABLE 267. INDONESIA BUDESONIDE INHALER MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 268. INDONESIA BUDESONIDE INHALER MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 269. INDONESIA BUDESONIDE INHALER MARKET SIZE, BY GERIATRIC, 2018-2030 (USD MILLION)
TABLE 270. INDONESIA BUDESONIDE INHALER MARKET SIZE, BY LATE GERIATRIC, 2018-2030 (USD MILLION)
TABLE 271. INDONESIA BUDESONIDE INHALER MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 272. INDONESIA BUDESONIDE INHALER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 273. INDONESIA BUDESONIDE INHALER MARKET SIZE, BY ASTHMA, 2018-2030 (USD MILLION)
TABLE 274. INDONESIA BUDESONIDE INHALER MARKET SIZE, BY SEVERE PERSISTENT ASTHMA, 2018-2030 (USD MILLION)
TABLE 275. INDONESIA BUDESONIDE INHALER MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
TABLE 276. INDONESIA BUDESONIDE INHALER MARKET SIZE, BY MODE OF DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 277. INDONESIA BUDESONIDE INHALER MARKET SIZE, BY PRESCRIPTION BASED INHALERS, 2018-2030 (USD MILLION)
TABLE 278. INDONESIA BUDESONIDE INHALER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 279. INDONESIA BUDESONIDE INHALER MARKET SIZE, BY PRODUCT FORMAT, 2018-2030 (USD MILLION)
TABLE 280. INDONESIA BUDESONIDE INHALER MARKET SIZE, BY MULTI-DOSE PACKS, 2018-2030 (USD MILLION)
TABLE 281. JAPAN BUDESONIDE INHALER MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 282. JAPAN BUDESONIDE INHALER MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
TABLE 283. JAPAN BUDESONIDE INHALER MARKET SIZE, BY DRY POWDER INHALERS, 2018-2030 (USD MILLION)
TABLE 284. JAPAN BUDESONIDE INHALER MARKET SIZE, BY METERED-DOSE INHALERS, 2018-2030 (USD MILLION)
TABLE 285. JAPAN BUDESONIDE INHALER MARKET SIZE, BY NEBULIZERS, 2018-2030 (USD MILLION)
TABLE 286. JAPAN BUDESONIDE INHALER MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 287. JAPAN BUDESONIDE INHALER MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 288. JAPAN BUDESONIDE INHALER MARKET SIZE, BY GERIATRIC, 2018-2030 (USD MILLION)
TABLE 289. JAPAN BUDESONIDE INHALER MARKET SIZE, BY LATE GERIATRIC, 2018-2030 (USD MILLION)
TABLE 290. JAPAN BUDESONIDE INHALER MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 291. JAPAN BUDESONIDE INHALER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 292. JAPAN BUDESONIDE INHALER MARKET SIZE, BY ASTHMA, 2018-2030 (USD MILLION)
TABLE 293. JAPAN BUDESONIDE INHALER MARKET SIZE, BY SEVERE PERSISTENT ASTHMA, 2018-2030 (USD MILLION)
TABLE 294. JAPAN BUDESONIDE INHALER MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
TABLE 295. JAPAN BUDESONIDE INHALER MARKET SIZE, BY MODE OF DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 296. JAPAN BUDESONIDE INHALER MARKET SIZE, BY PRESCRIPTION BASED INHALERS, 2018-2030 (USD MILLION)
TABLE 297. JAPAN BUDESONIDE INHALER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 298. JAPAN BUDESONIDE INHALER MARKET SIZE, BY PRODUCT FORMAT, 2018-2030 (USD MILLION)
TABLE 299. JAPAN BUDESONIDE INHALER MARKET SIZE, BY MULTI-DOSE PACKS, 2018-2030 (USD MILLION)
TABLE 300. MALAYSIA BUDESONIDE INHALER MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 301. MALAYSIA BUDESONIDE INHALER MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
TABLE 302. MALAYSIA BUDESONIDE INHALER MARKET SIZE, BY DRY POWDER INHALERS, 2018-2030 (USD MILLION)
TABLE 303. MALAYSIA BUDESONIDE INHALER MARKET SIZE, BY METERED-DOSE INHALERS, 2018-2030 (USD MILLION)
TABLE 304. MALAYSIA BUDESONIDE INHALER MARKET SIZE, BY NEBULIZERS, 2018-2030 (USD MILLION)
TABLE 305. MALAYSIA BUDESONIDE INHALER MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 306. MALAYSIA BUDESONIDE INHALER MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 307. MALAYSIA BUDESONIDE INHALER MARKET SIZE, BY GERIATRIC, 2018-2030 (USD MILLION)
TABLE 308. MALAYSIA BUDESONIDE INHALER MARKET SIZE, BY LATE GERIATRIC, 2018-2030 (USD MILLION)
TABLE 309. MALAYSIA BUDESONIDE INHALER MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 310. MALAYSIA BUDESONIDE INHALER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 311. MALAYSIA BUDESONIDE INHALER MARKET SIZE, BY ASTHMA, 2018-2030 (USD MILLION)
TABLE 312. MALAYSIA BUDESONIDE INHALER MARKET SIZE, BY SEVERE PERSISTENT ASTHMA, 2018-2030 (USD MILLION)
TABLE 313. MALAYSIA BUDESONIDE INHALER MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
TABLE 314. MALAYSIA BUDESONIDE INHALER MARKET SIZE, BY MODE OF DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 315. MALAYSIA BUDESONIDE INHALER MARKET SIZE, BY PRESCRIPTION BASED INHALERS, 2018-2030 (USD MILLION)
TABLE 316. MALAYSIA BUDESONIDE INHALER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 317. MALAYSIA BUDESONIDE INHALER MARKET SIZE, BY PRODUCT FORMAT, 2018-2030 (USD MILLION)
TABLE 318. MALAYSIA BUDESONIDE INHALER MARKET SIZE, BY MULTI-DOSE PACKS, 2018-2030 (USD MILLION)
TABLE 319. PHILIPPINES BUDESONIDE INHALER MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 320. PHILIPPINES BUDESONIDE INHALER MARKET SIZE, BY INHALERS, 2018-2030 (USD MILLION)
TABLE 321. PHILIPPINES BUDESONIDE INHALER MARKET SIZE, BY DRY POWDER INHALERS, 2018-2030 (USD MILLION)
TABLE 322. PHILIPPINES BUDESONIDE INHALER MARKET SIZE, BY METERED-DOSE INHALERS, 2018-2030 (USD MILLION)
TABLE 323. PHILIPPINES BUDESONIDE INHALER MARKET SIZE, BY NEBULIZERS, 2018-2030 (USD MILLION)
TABLE 324. PHILIPPINES BUDESONIDE INHALER MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 325. PHILIPPINES BUDESONIDE INHALER MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 326. PHILIPPINES BUDESONIDE INHALER MARKET SIZE, BY GERIATRIC, 2018-2030 (USD MILLION)
TABLE 327. PHILIPPINES BUDESONIDE INHALER MARKET SIZE, BY LATE GERIATRIC, 2018-2030 (USD MILLION)
TABLE 328. PHILIPPINES BUDESONIDE INHALER MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 329. PHILIPPINES BUDESONIDE INHALER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 330. PHILIPPINES BUDESONIDE INHALER MARKET SIZE, BY ASTHMA, 2018-2030 (USD MILLION)
TABLE 331. PHILIPPINES BUDESONIDE INHALER MARKET SIZE, BY SEVERE PERSISTENT ASTHMA, 2018-2030 (USD MILLION)
TABLE 332. PHILIPPINES BUDESONIDE INHALER MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2030 (USD MILLION)
TABLE 333. PHILIPPINES BUDESONIDE INHALER MARKET SIZE, BY MODE OF DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 334. PHILIPPINES BUDESONIDE INHALER MARKET SIZE, BY PRESCRIPTION BASED INHALERS, 2018-2030 (USD MILLION)
TABLE 335. PHILIPPINES BUDESONIDE INHALER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 336. PHILIPPINES BUDESONIDE INHALER MARKET SIZE, BY PRODUCT FORMAT, 2018-2030 (USD MILLION)
TABLE 337. PHILIPPINES BUDESONIDE INHALER MARKET SIZE, BY MULTI-DOSE PACKS, 2018-2030 (USD MILLION)
TABLE 338. SINGAPORE BUDESONIDE INHALER MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
TABLE 339. SINGAPORE BUDESONIDE INHALER MARKET SIZE, BY INHALERS, 2

Companies Mentioned

  • Abbott Laboratories
  • AstraZeneca PLC
  • Chiesi Farmaceutici S.p.A.
  • Cipla Limited
  • Cosmo Pharmaceuticals N.V.
  • Lunan Pharmaceutical Group
  • Lupin Limited
  • Manus Aktteva Biopharma LLP
  • Novartis International AG
  • Orion Corporation
  • Pfizer Inc.
  • Synmosa Biopharma Corporation
  • Takeda Pharmaceutical Company Limited
  • Viatris Inc.

Methodology

Loading
LOADING...

Related Topics

Related Reports

Budesonide Aerosol Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Budesonide Aerosol Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 96 Pages
  • Global
From
Budesonide Spray Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Budesonide Spray Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 95 Pages
  • Global
From
Smart Inhalers Market by Product Type, Indication, Distribution Channel - Global Forecast 2025-2030 - Product Image

Smart Inhalers Market by Product Type, Indication, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 197 Pages
  • Global
From
Smart Inhalers Market Size, Share & Trends Analysis Report By Type (Dry Powdered Inhalers, Metered Dose Inhalers), By Indication (Asthma, COPD), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies), By End Use, By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Smart Inhalers Market Size, Share & Trends Analysis Report By Type (Dry Powdered Inhalers, Metered Dose Inhalers), By Indication (Asthma, COPD), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies), By End Use, By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 125 Pages
  • Global
From
Digital Dose Inhaler Market by Type of Inhaler, Application, End-user, Component, Delivery Route, Prescription Type, Patient Age Group, Product Feature, Technology, Mode of Operation - Global Forecast 2025-2030 - Product Image

Digital Dose Inhaler Market by Type of Inhaler, Application, End-user, Component, Delivery Route, Prescription Type, Patient Age Group, Product Feature, Technology, Mode of Operation - Global Forecast 2025-2030

  • Report
  • 198 Pages
  • Global
From

About the Inhaler Market

The Budesonide Inhaler market is a segment of the larger Respiratory Drugs market. It is composed of inhalers that contain budesonide, a corticosteroid used to treat asthma and other respiratory conditions. Budesonide inhalers are used to reduce inflammation in the airways, allowing for easier breathing. They are also used to prevent asthma attacks and reduce the severity of symptoms. Budesonide inhalers are available in both pressurized metered-dose inhalers (pMDIs) and dry powder inhalers (DPIs). The Budesonide Inhaler market is highly competitive, with many companies offering different types of inhalers. Some of the major players in the market include GlaxoSmithKline, AstraZeneca, Merck, Teva Pharmaceuticals, and Mylan. Other companies such as Boehringer Ingelheim, Novartis, and Sunovion also offer budesonide inhalers. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.